Back

Biosecurity & Bioscience

LLNL and BridgeBio announce trials for supercomputing-discovered cancer drug

In a substantial milestone for supercomputing-aided drug design, Lawrence Livermore National Laboratory (LLNL) and BridgeBio Oncology Therapeutics (BridgeBio) today announced clinical trials have begun for a first-in-class medication that targets specific genetic mutations implicated in many types of cancer. The development of the new drug — BBO-8520 — is the result of…

GUIDE team develops approach to redesign antibodies against viral pandemics

In a groundbreaking development for addressing future viral pandemics, a multi-institutional team involving Lawrence Livermore National Laboratory (LLNL) researchers has successfully combined an artificial intelligence (AI)-backed platform with supercomputing to redesign and restore the effectiveness of antibodies whose ability to fight viruses has been compromised by…

Metal ion solvation in ionic liquids

Understanding the behavior of metal ions in room temperature ionic liquids is essential for predicting and optimizing performance for technologies like metal electrodeposition. A recent paper by Livermore researchers describes a first-principles molecular dynamics simulations approach to understanding and comparing the key structural properties metal ions (Cu+ and Ag+) in…